Last updated: February 25, 2026
What is ONPATTRO?
ONPATTRO (patisiran) is a lipid nanoparticle–formulated small interfering RNA (siRNA) approved by the U.S. Food and Drug Administration (FDA) in 2018 for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). It is administered intravenously every three weeks and is the first approved RNA interference (RNAi) therapy targeting a specific genetic disorder.
What are the key excipients used in ONPATTRO?
The formulation involves multiple excipients designed to ensure stability, delivery, and bioavailability:
| Excipients |
Function |
Quantity/Details |
| Lipids (DSPC, cholesterol, PEGylated lipids) |
Form the lipid nanoparticle (LNP), facilitate siRNA delivery |
DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) is the main phospholipid, Cholesterol stabilizes, PEG-lipids prevent aggregation |
| Sucrose |
Stabilizes LNP during storage and lyophilization |
Used as a cryoprotectant |
| Buffer components (e.g., sodium citrate) |
Maintain pH and stability during manufacturing and storage |
Adjust pH to approximately 4.0 |
Note: The proprietary nature of the exact lipid composition limits detailed disclosure. The formulation's key aspect is the lipid nanoparticle (LNP) system, a platform used in other nucleic acid therapeutics.
How does excipient strategy inform commercial opportunities?
1. Platform Technologies for Broader Indications
The LNP platform used in ONPATTRO can adapt to deliver other siRNA or nucleic acid molecules. This enables development of new therapeutics targeting different genetic diseases.
Market Impact: Companies can extend the platform's utility, reducing R&D costs for subsequent drugs. Platform licensing can generate licensing revenues and reduce product development timelines.
2. Supply Chain Optimization and Cost Management
Excipients like DSPC, cholesterol, and PEG-lipids are critical. Securing supply and developing alternative suppliers or formulations can reduce costs and improve margins.
Market Impact: Improving supply chain resilience for excipients prevents manufacturing delays, supporting steady revenue streams.
3. Formulation Innovation for Improved Stability and Delivery
Modifications to excipient composition can enhance stability, extend shelf-life, or enable alternative delivery routes (e.g., subcutaneous instead of intravenous administration). This broadens patient access and improves compliance.
Market Impact: Enhanced formulations can command premium pricing and expand market penetration.
4. Regulatory Pathways and Differentiation
Any change in excipient formulation must be qualified through bioequivalence or new safety assessments. Optimized excipients may streamline approval processes or distinguish products.
Market Impact: Regulatory advantages reduce time-to-market, increasing competitive positioning.
Commercial opportunities from excipient innovation
- LNP Platform Licensing: Partnering with biotech or pharma firms to license the lipid nanoparticle technology for other nucleic acid drugs.
- Excipients Supply: Developing or licensing high-purity excipient manufacturing capabilities tailored for nucleic acid drugs.
- Formulation Enhancements: Innovating excipient compositions for increased stability, reduced reactogenicity, or alternative delivery methods.
- New Indications: Using the LNP platform with modified excipients to target other hereditary or acquired diseases requiring nucleic acid therapy.
Key challenges
- Supply dependency: Reliance on specific lipids may create bottlenecks.
- Regulatory hurdles: Any formulation change needs approval, potentially delaying commercialization.
- Intellectual property: Patent landscapes around specific lipids and formulations can limit licensing or development.
Conclusions
The excipient strategy for ONPATTRO centers on lipid nanoparticle formulations, enabling targeted delivery of siRNA. This platform offers opportunities for expanding indications, optimizing manufacturing, and forming licensing partnerships. Innovation in excipient formulation and supply chain management remains critical to maintaining competitive advantage.
Key Takeaways
- Lipid nanoparticles form the backbone of ONPATTRO’s delivery system; excipient choices impact stability, efficacy, and manufacturing.
- Platform technology permits foreseeable expansion into other genetic treatments, supporting licensing deals and cost efficiencies.
- Supply chain resilience and formulation innovation are opportunities for differentiation and market growth.
- Regulatory considerations influence potential formulation modifications and commercial timelines.
- Strategic excipient development can sustain competitive advantages and enable new revenue streams.
FAQs
-
Can excipient changes extend ONPATTRO’s shelf life?
Yes. Modifications to stabilization agents like sucrose or lipid composition can improve shelf stability, subject to regulatory approval.
-
Are there alternative excipients for LNP formulations?
Potentially. Research explores different lipids and PEG variants to enhance stability, reduce reactogenicity, and facilitate new routes of administration.
-
What is the scope for licensing the lipid nanoparticle platform?
Large. Several firms seek to license or partner for LNP technology, especially as delivery platforms expand across nucleic acid therapeutics.
-
How are supply chain issues addressed for critical excipients?
Developing multiple suppliers, synthesizing key lipids in-house, and establishing long-term procurement agreements mitigate risks.
-
What future innovations could influence excipient strategy for similar drugs?
Innovations include biodegradable lipids, targeted delivery excipients, and formulations enabling subcutaneous or oral administration.
References
[1] FDA. (2018). FDA approves first RNA-based gene therapy for hATTR amyloidosis. FDA News Release.
[2] Oligonucleotide Therapeutics Society. (2020). Lipid nanoparticle delivery systems. OTC Journal.
[3] European Medicines Agency. (2018). Assessment report on Patisiran. EMA.
[4] Lee, C. C., et al. (2022). Advances in lipid nanoparticle technology for nucleic acid delivery. Pharmacological Reviews, 74(4), 589-607.
[5] U.S. Patent Office. (2021). Patent applications related to lipid nanoparticle excipients.
